-
1
-
-
83955165920
-
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumors resectable
-
Barber TW, Hofman MS, Thomson BN et al (2012) The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumors resectable. Eur J Surg Oncol 38:64-71
-
(2012)
Eur J Surg Oncol
, vol.38
, pp. 64-71
-
-
Barber, T.W.1
Hofman, M.S.2
Thomson, B.N.3
-
2
-
-
33750592324
-
Dosimetry in peptide radionuclide receptor therapy: A review
-
Cremonesi M, Ferrari M, Bodei L et al (2006) Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 47:467-1475
-
(2006)
J Nucl Med
, vol.47
, pp. 467-1475
-
-
Cremonesi, M.1
Ferrari, M.2
Bodei, L.3
-
3
-
-
0043132282
-
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon Alfa Study Group
-
DOI 10.1200/JCO.2003.12.142
-
Faiss S, Pape UF, Bohming M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the international lanreotide and interferon alfa study group. J Clin Oncol 21:2689-2696 (Pubitemid 46606312)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.14
, pp. 2689-2696
-
-
Faiss, S.1
Pape, U.-F.2
Bohmig, M.3
Dorffel, Y.4
Mansmann, U.5
Golder, W.6
Riecken, E.O.7
Wiedenmann, B.8
-
4
-
-
74049086575
-
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor
-
Kaemmerer D, Prasad V, DaffnerWet al (2009) Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15:5867-5870
-
(2009)
World J Gastroenterol
, vol.15
, pp. 5867-5870
-
-
Kaemmerer, D.1
Prasad, V.2
Daffner, W.3
-
5
-
-
33747589429
-
Resection of pancreatic neuroendocrine tumors: Results of 70 cases
-
DOI 10.1001/archsurg.141.8.765
-
Kazanjian KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors: Results of 70 cases. Arch Surg 141:765-769 (Pubitemid 44268515)
-
(2006)
Archives of Surgery
, vol.141
, Issue.8
, pp. 765-769
-
-
Kazanjian, K.K.1
Reber, H.A.2
Hines, O.J.3
-
6
-
-
70049091797
-
Nonfunctioning neuroendocrine pancreatic tumors: Our experience and management
-
Nomura N, Fujii T, Kanazumi N et al (2009) Nonfunctioning neuroendocrine pancreatic tumors: Our experience and management. J Hepatobiliary Pancreat Surgery 16:639-647
-
(2009)
J Hepatobiliary Pancreat Surgery
, vol.16
, pp. 639-647
-
-
Nomura, N.1
Fujii, T.2
Kanazumi, N.3
-
7
-
-
3442884868
-
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
-
DOI 10.1093/annonc/mdh216
-
Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966-973 (Pubitemid 39004355)
-
(2004)
Annals of Oncology
, vol.15
, Issue.6
, pp. 966-973
-
-
Oberg, K.1
Kvols, L.2
Caplin, M.3
Dell Fave, G.4
De Herder, W.5
Rindi, G.6
Ruszniewski, P.7
Woltering, E.A.8
Wiedenmann, B.9
-
8
-
-
70350442637
-
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumor: A report from the PROMID study group
-
Rinke A, Muller HH, Schade- Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumor: A report from the PROMID study group. J Clin Oncol 27:4656-4663
-
(2009)
J Clin Oncol
, vol.27
, pp. 4656-4663
-
-
Rinke, A.1
Muller, H.H.2
Schade-Brittinger, C.3
-
9
-
-
80455174802
-
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs)
-
Sowa-Staszczak A, Pach D, Chrzan R et al (2011) Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs). Eur J Nucl Med Mol Imaging 38:1669-1674
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 1669-1674
-
-
Sowa-Staszczak, A.1
Pach, D.2
Chrzan, R.3
-
10
-
-
77950890318
-
Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor
-
Stoeltzing O, Loss M, Huber M et al (2010) Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395:185-192
-
(2010)
Langenbecks Arch Surg
, vol.395
, pp. 185-192
-
-
Stoeltzing, O.1
Loss, M.2
Huber, M.3
|